New Data on Combination Treatments for Melanoma
Vemurafenib + cobimetinib achieves significant progression-free survival and response rates in melanoma. Phase III trial data shows better outcomes with combination therapy than vemurafenib alone.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Vemurafenib + cobimetinib achieves significant progression-free survival and response rates in melanoma. Phase III trial data shows better outcomes with combination therapy than vemurafenib alone.
Experts are divided on the value of lung cancer vaccination after disappointing results from the MAGRIT phase III trial.
Treatments for advanced cancer are often unavailable or available only at substantial out of pocket cost in many Eastern European countries compared to those in Western Europe
Dual targeting with pertuzumab and trastuzumab plus chemotherapy has become the new standard therapy in metastatic HER2 positive breast cancer
More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them
New initiative aims to promote exchange of ideas among female oncologists and support women with cancer in Greece
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival
Long-term follow-up from CLEOPATRA study presented at ESMO 2014 demonstrates ‘unprecedented’ benefit
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy.
Phase III trials presented at the ESMO 2014 Congress report major advances in supportive care for cancer patients.
Study using thymidylate synthase as a predictive and prospective biomarker. Report on a trial with a drug that targets the folate receptor.
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.